Literature DB >> 26171012

Reduced ubiquitin-specific protease 9X expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cells.

Huiwen Hu1, Chengyong Tang2, Qinghu Jiang1, Wei Luo1, Jiming Liu1, Xufu Wei1, Rui Liu1, Zhongjun Wu1.   

Abstract

Ubiquitin-specific protease 9X (USP9X) is crucial in many tumor types, but not in hepatocellular carcinoma (HCC). The current study aimed to examine the effects of RNA interference on USP9X expression, and subsequently on the bioactivity of HCC SMMC7721 and HepG2 cells. The protein expression of USP9X in SMMC7721, HepG2 and normal human liver cell line L02 at the cellular level was determined by western blot analysis; USP9X was knocked down by small interfering RNA (siRNA) in HCC SMMC7721 and HepG2 cells. In vitro cell viability was assessed by MTT assay, apoptosis was determined by flow cytometry (FCM) and cell migration was evaluated by Transwell assays. The protein expression of USP9X in SMMC7721 and HepG2 were both significantly higher than that in L02 (P<0.01). The results of western blot demonstrated that the USP9X-siRNA could efficiently inhibit USP9X expression when compared with that of the negative control (NC) group (P<0.01) and MTT assay demonstrated that cell proliferation in USP9X-blocked cells was significantly reduced when compared with that of the NC group (P<0.01). The results of FCM revealed that apoptosis was significantly increased in USP9X-blocked cells when compared with that of the NC group (P<0.01). The results of transwell assay showed that cell migration was significantly inhibited in USP9X-blocked cells when compared with that of the NC group (P<0.01). These results show that expression of USP9X is upregulated in hepatoma cells SMMC7721 and HepG2, and that downregulating USP9X by siRNA may induce cell apoptosis, inhibit cell growth and cell migration in the HCC SMMC7721 and HepG2 cell lines. USP9X may therefore be a potential target for HCC treatment and early detection.

Entities:  

Keywords:  RNA interference; apoptosis; growth; hepatocellular carcinoma; migration; ubiquitin-specific protease 9X

Year:  2015        PMID: 26171012      PMCID: PMC4487130          DOI: 10.3892/ol.2015.3152

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  16 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Ubiquitin-dependent regulation of the synapse.

Authors:  Aaron DiAntonio; Linda Hicke
Journal:  Annu Rev Neurosci       Date:  2004       Impact factor: 12.449

3.  Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.

Authors:  Wolfgang Sieghart; Doris Losert; Sabine Strommer; Daniel Cejka; Katharina Schmid; Susanne Rasoul-Rockenschaub; Martin Bodingbauer; Richard Crevenna; Brett P Monia; Markus Peck-Radosavljevic; Volker Wacheck
Journal:  J Hepatol       Date:  2005-10-25       Impact factor: 25.083

4.  Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.

Authors:  Martin Schwickart; Xiaodong Huang; Jennie R Lill; Jinfeng Liu; Ronald Ferrando; Dorothy M French; Heather Maecker; Karen O'Rourke; Fernando Bazan; Jeffrey Eastham-Anderson; Peng Yue; David Dornan; David C S Huang; Vishva M Dixit
Journal:  Nature       Date:  2009-12-20       Impact factor: 49.962

5.  Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics.

Authors:  Shishan Deng; Hongying Zhou; Ruohong Xiong; Youguang Lu; Dazhong Yan; Tianyong Xing; Lihua Dong; Enjie Tang; Huijun Yang
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

Review 6.  Multidisciplinary management of hepatocellular carcinoma: where are we today?

Authors:  Jorge A Marrero
Journal:  Semin Liver Dis       Date:  2013-03-01       Impact factor: 6.115

Review 7.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

Review 8.  Evolution of systemic therapy of advanced hepatocellular carcinoma.

Authors:  Thomas Yau; Pierre Chan; Richard Epstein; Ronnie-T Poon
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

9.  Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.

Authors:  Henning Schulze-Bergkamen; Binje Fleischer; Marcus Schuchmann; Achim Weber; Arndt Weinmann; Peter H Krammer; Peter R Galle
Journal:  BMC Cancer       Date:  2006-10-02       Impact factor: 4.430

10.  The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.

Authors:  Chander Peddaboina; Daniel Jupiter; Steven Fletcher; Jeremy L Yap; Arun Rai; Richard P Tobin; Weihua Jiang; Philip Rascoe; M Karen Newell Rogers; W Roy Smythe; Xiaobo Cao
Journal:  BMC Cancer       Date:  2012-11-21       Impact factor: 4.430

View more
  3 in total

Review 1.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.

Authors:  Jean-François Spinella; Pauline Cassart; Chantal Richer; Virginie Saillour; Manon Ouimet; Sylvie Langlois; Pascal St-Onge; Thomas Sontag; Jasmine Healy; Mark D Minden; Daniel Sinnett
Journal:  Oncotarget       Date:  2016-10-04

3.  WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia.

Authors:  Hao Luo; Bo Jing; Yu Xia; Yugen Zhang; Meng Hu; Haiyan Cai; Yin Tong; Li Zhou; Li Yang; Junmei Yang; Hu Lei; Hanzhang Xu; Chuanxu Liu; Yingli Wu
Journal:  Cancer Cell Int       Date:  2019-03-13       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.